NewAmsterdam Pharma (NAMS) Competitors $25.31 +2.35 (+10.24%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$25.14 -0.16 (-0.65%) As of 08/8/2025 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NAMS vs. BBIO, VRNA, BPMC, ROIV, GRFS, LEGN, ELAN, RVMD, RYTM, and NUVLShould you be buying NewAmsterdam Pharma stock or one of its competitors? The main competitors of NewAmsterdam Pharma include BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Grifols (GRFS), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry. NewAmsterdam Pharma vs. Its Competitors BridgeBio Pharma Verona Pharma PLC American Depositary Share Blueprint Medicines Roivant Sciences Grifols Legend Biotech Elanco Animal Health Revolution Medicines Rhythm Pharmaceuticals Nuvalent NewAmsterdam Pharma (NASDAQ:NAMS) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk. Does the media prefer NAMS or BBIO? In the previous week, BridgeBio Pharma had 20 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 33 mentions for BridgeBio Pharma and 13 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.68 beat BridgeBio Pharma's score of 0.49 indicating that NewAmsterdam Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 10 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, NAMS or BBIO? NewAmsterdam Pharma has a beta of -0.02, meaning that its share price is 102% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Is NAMS or BBIO more profitable? NewAmsterdam Pharma has a net margin of -259.07% compared to BridgeBio Pharma's net margin of -329.25%. BridgeBio Pharma's return on equity of 0.00% beat NewAmsterdam Pharma's return on equity.Company Net Margins Return on Equity Return on Assets NewAmsterdam Pharma-259.07% -27.27% -25.00% BridgeBio Pharma -329.25%N/A -85.69% Do analysts prefer NAMS or BBIO? NewAmsterdam Pharma presently has a consensus target price of $41.20, indicating a potential upside of 62.78%. BridgeBio Pharma has a consensus target price of $61.35, indicating a potential upside of 31.72%. Given NewAmsterdam Pharma's higher probable upside, research analysts clearly believe NewAmsterdam Pharma is more favorable than BridgeBio Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewAmsterdam Pharma 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89BridgeBio Pharma 0 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation and earnings, NAMS or BBIO? NewAmsterdam Pharma has higher earnings, but lower revenue than BridgeBio Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNewAmsterdam Pharma$45.56M62.37-$241.60M-$1.62-15.62BridgeBio Pharma$221.90M40.13-$535.76M-$4.09-11.39 Do institutionals & insiders have more ownership in NAMS or BBIO? 89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 20.8% of NewAmsterdam Pharma shares are held by insiders. Comparatively, 18.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryNewAmsterdam Pharma and BridgeBio Pharma tied by winning 8 of the 16 factors compared between the two stocks. Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NAMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAMS vs. The Competition Export to ExcelMetricNewAmsterdam PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.84B$2.42B$5.52B$9.72BDividend YieldN/A1.78%4.60%4.12%P/E Ratio-15.6220.5930.0124.75Price / Sales62.37694.84450.0597.82Price / CashN/A172.9536.7758.47Price / Book3.654.328.185.59Net Income-$241.60M$31.61M$3.26B$265.99M7 Day Performance18.94%0.01%6.13%5.06%1 Month Performance14.94%-1.53%0.07%0.61%1 Year Performance45.54%5.85%36.31%22.82% NewAmsterdam Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAMSNewAmsterdam Pharma3.5769 of 5 stars$25.31+10.2%$41.20+62.8%+45.5%$2.84B$45.56M-15.624News CoveragePositive NewsEarnings ReportAnalyst ForecastAnalyst RevisionHigh Trading VolumeBBIOBridgeBio Pharma4.7237 of 5 stars$47.75+0.8%$61.18+28.1%+90.7%$8.99B$221.90M-13.53400Trending NewsEarnings ReportAnalyst ForecastInsider TradeOptions VolumeAnalyst RevisionVRNAVerona Pharma PLC American Depositary Share1.5579 of 5 stars$105.47+0.3%$109.00+3.3%+365.4%$8.95B$42.28M-52.7430Positive NewsEarnings ReportInsider TradeBPMCBlueprint Medicines0.6453 of 5 stars$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640ROIVRoivant Sciences2.1503 of 5 stars$11.51+1.8%$16.50+43.4%+3.3%$7.69B$29.05M-46.04860Positive NewsUpcoming EarningsGRFSGrifols3.3304 of 5 stars$10.72-0.6%$10.30-3.9%+47.9%$7.41B$7.81B9.1623,822Positive NewsAnalyst ForecastLEGNLegend Biotech3.8262 of 5 stars$38.45-0.9%$73.33+90.7%-33.8%$7.13B$627.24M-65.172,609News CoverageUpcoming EarningsAnalyst RevisionELANElanco Animal Health3.3371 of 5 stars$14.07+2.1%$16.17+14.9%+27.4%$6.85B$4.44B19.029,000Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionRVMDRevolution Medicines4.3424 of 5 stars$37.18+1.5%$68.91+85.3%-18.4%$6.82B$11.58M-9.30250News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionRYTMRhythm Pharmaceuticals3.9966 of 5 stars$90.24+2.2%$91.93+1.9%+103.2%$5.62B$130.13M-32.11140Earnings ReportAnalyst ForecastAnalyst RevisionNUVLNuvalent3.1244 of 5 stars$78.35+0.8%$119.60+52.6%+5.9%$5.58BN/A-17.8540News CoverageEarnings ReportUpcoming EarningsInsider TradeAnalyst Revision Related Companies and Tools Related Companies BridgeBio Pharma Alternatives Verona Pharma PLC American Depositary Share Alternatives Blueprint Medicines Alternatives Roivant Sciences Alternatives Grifols Alternatives Legend Biotech Alternatives Elanco Animal Health Alternatives Revolution Medicines Alternatives Rhythm Pharmaceuticals Alternatives Nuvalent Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NAMS) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Company N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
